Halozyme Therapeutics (NASDAQ: HALO) has announced that it will be unveiling its third quarter financial results on Thursday 31st October 2024. The disclosure is planned to occur after market close.
As per the predictions of financial analysts on Wall Street, the company is set to report an estimated per share $0.98 profit for the third quarter. Additionally, the company is projected to unveil a revenue of $251.06 million for the period.
When looking back at the corresponding quarter from the previous year, the company's earnings report showcased a per-share income of $0.75. This was attributed to the company's total revenue, which amounted to an impressive $216.03 million during that same period.
Analysts have provided their projections for the company's full-year performance, revealing that they expect the company to generate a total revenue of $983.85 million. At the same time, the earnings per share for the company are also anticipated to reach profit of $3.96 during the fiscal year.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q2 2024 | $0.91 | +23.0% | 231.35 M | +4.7% |
| Q1 2024 | $0.79 | +68.1% | 195.88 M | +20.8% |
| Q4 2023 | $0.82 | +70.8% | 230.04 M | +26.7% |
| Q3 2023 | $0.75 | +1.4% | 216.03 M | +3.4% |
| Q2 2023 | $0.74 | +39.6% | 221.04 M | +45.1% |
| *Growth on year-over-year basis | ||||
Additionally, The company will host a conference call with investors and analysts on 31st October 2024 at 04:30 PM eastern time to review the Q3 2024 financial results.
Halozyme Therapeutics (HALO) shares traded as low as $50.10 and as high as $50.96 on a day volume of 538.20 thousand shares, closed Tuesday's regular trading session at $50.64, a rise of 0.36 percent.
